Aurora kinase inhibitors: Progress towards the clinic

0377543 - ÚOCHB 2013 RIV US eng J - Článek v odborném periodiku
Kollareddy, M. - Zheleva, D. - Dzubak, P. - Brahmkshatriya, Pathik - Lepšík, Martin - Hajduch, M.
Aurora kinase inhibitors: Progress towards the clinic.
Investigational New Drugs. Roč. 30, č. 6 (2012), s. 2411-2432. ISSN 0167-6997. E-ISSN 1573-0646
Grant ostatní: GA ČR(CZ) GA301/08/1649; GA ČR(CZ) GD303/09/H048
Program: GA; GD
Výzkumný záměr: CEZ:AV0Z40550506
Klíčová slova: Aurora kinases * cancer * inhibitors
Kód oboru RIV: CF - Fyzikální chemie a teoretická chemie
Impakt faktor: 3.498, rok: 2012

The Aurora kinases (serine/threonine kinases) were discovered in 1995 during studies of mutant alleles associated with abnormal spindle pole formation in Drosophila melanogaster. They soon became the focus of much attention because of their importance in human biology and association with cancer. Aurora kinases are essential for cell division and are primarily active during mitosis. Following their identification as potential targets for cancer chemotherapy, many Aurora kinase inhibitors have been discovered and developed. Currently, there are about 30 Aurora kinase inhibitors in different stages of pre-clinical and clinical development. This review summarizes the characteristics and status of Aurora kinase inhibitors in preclinical, Phase I, and Phase II clinical studies, with particular emphasis on the mechanisms of action and resistance to these promising anticancer agents.
Trvalý link: http://hdl.handle.net/11104/0209672